Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Gwen Alyce Lomberk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5463-789X; OpenAlex author ID A5063960706; NIH RePORTER profile ID 10538316. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 3)
Trials
0
Grants
3
Labs led
3
Collaborators
95
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper, 1 grant · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper, 1 grant · 2024: 2 papers · 2025: 1 paper, 1 grant · 2026: 2 papers

Papers 27

  1. PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. Last author DOI 10.3389/fcell.2026.1748541↗
  2. Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. Last author DOI 10.3390/epigenomes10010019↗
  3. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
  4. EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. Co-author DOI 10.1172/jci.insight.173746↗
  5. Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer First author DOI 10.21037/jgo-24-326↗
  6. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
  7. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  8. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  9. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
  10. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  11. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Co-author DOI 10.3389/fonc.2021.606820↗
  12. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. Last author DOI 10.1158/1541-7786.mcr-19-0490↗
  13. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1038/s41467-019-11812-7↗
  14. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cells8111453↗
  15. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  16. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  17. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  18. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. Co-author DOI 10.1038/cddis.2016.202↗
  19. The promise of epigenomic therapeutics in pancreatic cancer. Co-author DOI 10.2217/epi-2015-0016↗
  20. The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Co-author DOI 10.1016/j.suc.2015.05.011↗
  21. IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0896↗
  22. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Co-author DOI 10.1172/jci76037↗
  23. NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells. Co-author DOI 10.4161/auto.22258↗
  24. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. Co-author DOI 10.1002/emmm.201201255↗
  25. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. Co-author DOI 10.1172/jci60144↗
  26. Epigenetic silencing of tumor suppressor genes in pancreatic cancer. Co-author DOI 10.1007/s12029-011-9256-2↗
  27. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. Co-author DOI 10.1074/jbc.m110.197533↗

Grants 3

  1. Targeting Epigenomic Regulators at the Replication Fork in PDAC R01CA247898↗
  2. Epigenomic Regulation in Pancreatic Cell Growth R01DK052913↗
  3. Novel Experimental Therapeutics for Pancreatic Cancer R01CA178627↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Raul A. Urrutia · 25 shared papers, 1 shared grant, 2011–2026 · strength 3.67
  2. Juan Iovanna · 18 shared papers, 2012–2026 · strength 1.79
  3. Nelson Dusetti · 12 shared papers, 2016–2025 · strength 1.39
  4. Michael T. Zimmermann · 5 shared papers, 2021–2026 · strength 1.15
  5. Gareth Pollin · 3 shared papers, 2024–2026 · strength 0.87
  6. Nicolas Alejandro Fraunhoffer · 4 shared papers, 2021–2025 · strength 0.68
  7. Analía Meilerman Abuelafia · 3 shared papers, 2022–2025 · strength 0.56
  8. Rémy Nicolle · 5 shared papers, 2017–2023 · strength 0.46
  9. Odile Gayet · 5 shared papers, 2017–2022 · strength 0.42
  10. Patricia Santofimia‐Castaño · 2 shared papers, 2019–2025 · strength 0.33
  11. Daniel Grasso · 3 shared papers, 2013–2025 · strength 0.32
  12. Julie Roques · 3 shared papers, 2017–2022 · strength 0.32
  13. Abdessamad El Kaoutari · 2 shared papers, 2021–2024 · strength 0.29
  14. Eduardo Chuluyán · 2 shared papers, 2015–2025 · strength 0.29
  15. Madeline M. Dzikowski · 1 shared paper, 2026 · strength 0.29
  16. Céline Loncle · 6 shared papers, 2012–2017 · strength 0.26
  17. Matías Estarás · 1 shared paper, 2025 · strength 0.25
  18. Philippe Soubeyran · 2 shared papers, 2019–2021 · strength 0.21
  19. Dieter Saur · 2 shared papers, 2021–2022 · strength 0.21
  20. Véronique Secq · 4 shared papers, 2012–2018 · strength 0.17
  21. Olivıer Turrini · 4 shared papers, 2012–2018 · strength 0.17
  22. Emilie Jaune · 1 shared paper, 2024 · strength 0.17
  23. Fatemeh Mousavi · 1 shared paper, 2024 · strength 0.17
  24. Christopher L. Pin · 1 shared paper, 2024 · strength 0.17
  25. Benjamin Bian · 3 shared papers, 2017–2018 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.